

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Rainer KLOCKE, et al.)
)
Serial No. 10/527,769) **CONFIRMATION NO.: 5191**
)
Filed: December 5, 2005) Group Art Unit: 1646
)
For: CYTOPLASMIC DYNEIN HEAVY CHAIN1 GENES,) **ATTORNEY DOCKET NO. ING-121**
EXPRESSION PRODUCTS, NON-HUMAN ANIMAL)
MODEL: USES IN HUMAN NEUROLOGICAL)
DISEASES)
)
Examiner: Not Yet Assigned)

INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, §1.97 and §1.98, documents that may be material to the examination of this application are listed on the attached forms PTO/SB/08B. In accordance with the waiver of Rule 1.98(a)(2)(I), (OG Notice of August 5, 2003), copies of U.S. patents are not enclosed, and a copy of each listed foreign patent document and non-patent document is enclosed.

The cited documents disclose numerous specific features. There has been no attempt to enumerate each and every feature disclosed by each document, however. The Examiner is requested to review these documents and to determine the extent of the materiality of the document disclosures, if any, with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular

U.S. Serial No.: 10/527,769
Attorney Docket No.: ING-121

-2-

IDS Dated: February 13, 2008

date which may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.

Applicants reserve the right to later set forth how the claimed invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and documents recited herein, as well as documents that may be cited by the Examiner in rejecting a claim in the instant patent application.

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,

Dated:

13 February 2008

By


Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & CEPURITIS, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180